US 12,303,515 B2
PIM1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof
Ming-Liang He, Hong Kong (CN); Ying Chen, Hong Kong (CN); Fanghang Zhou, Hong Kong (CN); and Qianya Wan, Hong Kong (CN)
Assigned to City University of Hong Kong, Hong Kong (CN)
Appl. No. 17/594,707
Filed by City University of Hong Kong, Hong Kong (CN)
PCT Filed Apr. 30, 2020, PCT No. PCT/CN2020/088009
§ 371(c)(1), (2) Date Oct. 27, 2021,
PCT Pub. No. WO2020/221334, PCT Pub. Date Nov. 5, 2020.
Claims priority of provisional application 62/840,819, filed on Apr. 30, 2019.
Prior Publication US 2022/0288087 A1, Sep. 15, 2022
Int. Cl. A61K 31/454 (2006.01); A61K 31/5025 (2006.01); A61K 31/551 (2006.01); A61K 31/7088 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 31/454 (2013.01); A61K 31/5025 (2013.01); A61K 31/7088 (2013.01); A61P 31/14 (2018.01)] 5 Claims
 
1. A method of reducing replication of an EV-A71 or Zika virus, the method comprising: administering, to a biological cell afflicted with the EV-A71 or Zika virus, an effective antiviral amount of a PIM1 inhibitor, wherein the PIM1 inhibitor is a ribonucleic acid interfering ribonucleic acid, or a compound comprising a structure of Formula (I), Formula (II), Formula (III) or a salt or solvate thereof:

OG Complex Work Unit Chemistry